Severe Obesity Clinical Trial
Official title:
GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Feasibility Trial
The goal of this pilot clinical trial is to determine the effectiveness of Tirzepatide in patients with persistent obesity (BMI > 30) 12 months after bariatric surgery (Roux-en-Y Gastric Bypass). The investigators also aim to determine the frequency of side effects with Tirzepatide in this patient population. Patients who take tirzepatide 12 months after bariatric surgery will be compared to patients who receive a placebo.
Obesity affects nearly half of the U.S. population, impacting health outcomes including diabetes, cardiovascular risk, longevity, and quality of life. While bariatric surgery such as gastric bypass stands as the most effective intervention, 65% of individuals experience persistent obesity when undergoing surgical weight loss alone. Given the wide-ranging impact of obesity on health outcomes, a critical need exists to explore the efficacy of adjuvant weight loss therapies after gastric bypass surgery. Tirzepatide (TRZ), a type of glucagon-like peptide-1 receptor agonist, shows remarkable effectiveness in medical obesity with 25% weight loss after sustained therapy. However, nearly two-thirds of patients taking medications like TRZ have mild to moderate gastrointestinal (GI) symptoms, including nausea, vomiting, and abdominal pain. These medication side-effects could be a consequence of gastroparesis via vagal stimulation of the stomach, and may represent a major driver of weight loss. Limited data exist regarding use of these newer agents, such as TRZ, in patients who have undergone gastric bypass, which disrupts vagal nerves responsible for managing food transit and gastric emptying. This is a major and timely scientific gap in understanding whether gastric bypass surgery might mitigate these GI symptoms while allowing for enhanced weight loss with adjuvant TRZ use in the post-operative period. The investigators propose a pilot, phase II, open-label trial enrolling patients twelve months after gastric bypass with a nadir Body Mass Index ≥ 30 kg/m2. Study subjects will be randomized to either 24 weeks of TRZ or post-surgery standard of care. Our proposal consists of two aims. First, the investigators will determine the impact of adjuvant TRZ administration on weight, total fat mass, and lean body mass in patients with a history of gastric bypass (Aim 1). Second, the investigators aim to investigate the frequency and severity of GI discomfort associated with TRZ utilizing a validated patient reported outcome questionnaire, and they will investigate the impact of TRZ on GI motility in patients with prior Gastric Bypass (Aim 2). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03690752 -
Adherence to Walking on an Alter G Anti-Gravity Treadmill
|
N/A | |
| Active, not recruiting |
NCT02767505 -
Bypass Equipoise Sleeve Trial (BEST)
|
N/A | |
| Recruiting |
NCT05786092 -
Impact of Telemonitoring on Metabolic Variables in Severe Obesity
|
N/A | |
| Active, not recruiting |
NCT03249441 -
Compassion-Focused Therapy for People With Severe Obesity.
|
N/A | |
| Terminated |
NCT04626232 -
Comparison of the Sleeve Gastrectomy Technique With a Nissen Fundoplication Added to the Conventional Sleeve Gastrectomy Technique in Morbidly Obese Patients
|
N/A | |
| Completed |
NCT02952963 -
Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass
|
Phase 4 | |
| Active, not recruiting |
NCT02374632 -
Gut Hormones as Mediators of Different Weight Loss Responses After Roux-en-Y Gastric Bypass
|
Phase 4 | |
| Active, not recruiting |
NCT04165694 -
Single Anastomosis Duodenal Ileal Bypass (SADI) for Sleeve Revision
|
N/A | |
| Completed |
NCT05409612 -
Trial Assessing the Immunogenicity and Safety of Two Influenza Vaccine Strategies Among Severe Obese Adult Patients
|
Phase 3 | |
| Completed |
NCT03638895 -
Energy Expenditure From ECAL Indirect Calorimeter in a Multicomponent Weight Management Service
|
N/A | |
| Not yet recruiting |
NCT05493592 -
Pigeon Peas (Cajanus Cajan) : a Natural Anti-inflammatory Facilitating Weight Loss in Obese Patients Returning to Sport?
|
N/A | |
| Completed |
NCT02823561 -
Garcinia Mangostana Extracts in the Management of Weight Loss
|
Phase 4 | |
| Completed |
NCT02340247 -
Effects of Bile Acids on GLP-1 Secretion After Roux-en-Y Gastric Bypass
|
Phase 4 | |
| Recruiting |
NCT02076880 -
SLEEVEDIAB To Explore the Early and Late Metabolic Effects of Sleeve Gastrectomy in Obese Patients
|
N/A | |
| Completed |
NCT04042493 -
Connect for Health Pediatric Weight Management Program
|
N/A | |
| Completed |
NCT04129801 -
Muscle Strength in Severe Obese Patients in the Postoperative of Bariatric Surgery
|
||
| Completed |
NCT05341414 -
Trajectories of Resilience and Bariatric Surgery Outcomes
|
||
| Recruiting |
NCT02710786 -
Comorbidity After Gastric Bypass
|
||
| Recruiting |
NCT02409160 -
Sleep and Immune Response in Severe Obese Patients Undergoing Bariatric Surgery.
|
N/A | |
| Completed |
NCT00623792 -
Study on Impact of Lifestyle Change and Weight Loss Before Bariatric Surgery
|
N/A |